TW203044B - - Google Patents
Download PDFInfo
- Publication number
- TW203044B TW203044B TW081105115A TW81105115A TW203044B TW 203044 B TW203044 B TW 203044B TW 081105115 A TW081105115 A TW 081105115A TW 81105115 A TW81105115 A TW 81105115A TW 203044 B TW203044 B TW 203044B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- group
- page
- item
- ministry
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
Description
Λ 6 Η 6 ^03044 五、發明説明(Ο 發明領域 本發明為關於3 -羥基-3-甲基戊二酸單醯輔_A (HMG-C ο A )還原酶抑制_ β 先前技術 抑制HMG-CoA邇原_活性以治療動脈硬化之第一代藥 物已知有Mevinolin (美國專利Νο·4,231,938), pravastatin納(美國專利 Νο·4, 346,227)和 sinvastatin (美國專利Νο·4,444,784),其為真齄代謝物或化學修 飾者。近來,HMG-CoA邇原酶之合成抑制劑如fluvastatin (F.G. Kathawala等人,8th Int'l Syaip. 〇n Atherosclerosis,摘要論文,第 445頁,鏟馬(1988)> 和BMY 22089 (英國專利No.2 ,202 ,846)被發展為第二 代_物。 發明概要 本發明化合物抑制於嫌固酵合成中扮演鼋要角色的 HMG-CoA還原酶,且其曲而抑制膽固酵的生物合$ 0 此,其可用於治療高躇固酵血症,离脂蛋白血症 和動 脈硬化。 詳細描述 (請先閱讀背面之注意事項再填寫本頁) 裝· 訂_ 經濟部屮央標準局貝工消費合作社印製 於 關 為 明 發 本
或R4 酯 内 琢 閉 的 醮 對 k,0304d Λ 6 Η 6 經濟部屮央標準局貝工消费合作社印奴 五、發明説明(i ) 其中R1為低烷基,芳基,或芳烷基,其各可具有一傾 以上取代基;R2和R3各自為氫,低烷基,或芳基,且 各低烷基和芳基可具有一個以上取代基;R4為氫,低 烷基,或可形成無毒製藥容許鹽之陽離子;X為硫,氣 ,或磺醯基,或亞胺基其可具有一取代基;點線代表雙 鍵之有或無本發明亦提供一種含其之醫藥組成物。 於説明書中,名詞「低烷基」意指直,支或環狀 C 1 - 6烷基,包括甲基,乙基,正丙基,異丙基,琛 丙基, 正丁基,異丁基,第二丁基,第三丁基 ,環丁基,正戊基,異戊基,新戊基,第三戊基,環戊 基,正己基,和異己基等。又,此低烷基可取代1至3 餹取代基獨立選自鹵素,胺基,和氰基。鹵素意指氱, 氣,溴和碘。 名詞「芳基」意指C6 芳族基包括苯基,甲苯基 ,二甲苯基,二苯基,策基等。此芳基可具有1至3個 取代基獨立選自低院基,鹵素,胺基,和《基。較佳芳 基為苯基取代以1至3値齒素。 名詞「芳烷基」意指Ci — 6低烷基取代以上述之 C6 -12芳族芳基。其例為苄基,苯乙基,苯丙基等, 其各可具有1至3個取代基獨立選自低烷基,鹵素,胺 基,氛基等。 名詞「可形成無毒製藥容許鹽之陽離子」意指鹼金屬 離子,齡土族離子,和銨離子。齡金屬之例為鋰,納, (請先閱讀背面之注意事項再塡寫本頁) 裝· 線· -4- 經濟部中央標準局员工消费合作社印製 L03044 Λ 6 _Β6_ 五、發明説明(士) 鉀,和鉋,且驗土金羼之例為波,鎂,和鈣。特別地, 較佳為納和鈣^ 「醯基」之例為甲醯基,乙醯基,丙醯基,丁醏基, 異丁醯基,戊醛基,和異戊醯基》 名詞「被取代胺基為取代基」意指胺基被取代以磺醛 基和烷磺醛基。其例為磺醯胺基和甲磺醯胺基。 於名詞「亞胺基其可具有一取代基」,較佳取代基為 醯基,任意地被取代以胺基,和被取代以磺醯基。 名詞「被取代磺醯基為取代基」意指磺醛基被取代以 烷基,胺基,或烷胺基。其例為甲磺醯基,胺磺醛基, 甲基胺磺醛基,和Ν-二甲基胺磺醛基。 本發明化合物可以下列方法製備。 ⑴化合物§之羧酸鹽基藉由於適當鈍性溶劑如THF,醚 ,和甲苯在邇原劑如LiAlH4和DIBAL-H存在下之還原作 用轉變成醇基。反應在-70至5(TC下,較佳在近室溫下 ,進行1 0分鐘至1 Q小時,較佳為3 0分鐘至3小時。其後 將所得的醇令以於適當溶劑如二氣甲烷中氣化劑如TPAP /4 -甲基-嗎呋啉-N-氣化物或氛鉻酸吡錠存在下之氣化 作用可得醛化合物自。反應在Q-60°C下,較佳在近室溫 下,進行1 Q分鐘至1 〇小時,較佳為3 D分鐘至3小時。 (請先閱讀背面之注意事項再塡寫本頁)
03044 Λ 6 Η 6 五、發明説明(4 ) 其中R1 ,R2,和R3各如上定義,且Alkyl意指低烷基 ⑵所得化合物p令以與(3R) -或(3S)-3-(第三丁基二 甲基甲矽烷氣基-5-氣基-6-三苯磷丙環叉己酸衍生物於 適當溶劑如乙腈,二乙醚,四氫呋喃,和二甲基甲醯肢 中反應可得化合物£ «反應於加熱下進行1-3Q小時,較 佳為1 0 - 1 5小時。 〇 OSi(CH3)2t-Bu Rl-X^^R3 R2 c (請先閲讀背面之注意事項再填寫本頁) 裝· 經濟部中央標準局貝工消费合作社印製 其中c*為不對稱碩,點線為雙鍵之有或無,, R2 ,R 3 ,和R 4各同上定義。 ⑶化合物g令以於適當有機溶劑豳化氫存在中進行第 三丁基二甲基甲矽烷基之消除作用可得化合物g。 各種鹵化物均可用做為鹵化氫。其中,較佳為氟化氫 0 可使用同於步驟⑵中所用之有機溶劑。特佳為乙腈。 反應於0至6 0 °C ,較佳於室溫下進行0 . 5 - 1 0小時,較 佳為1 - 2小時。
d .¾ . 線. 太/f i«lfl 格m〇x297公贷) ^03044 Λ 6 _Η6_ 五、發明説明(t ) 其中C·,點線,R1 ,R 2 , R3,和R4各同上定義。 ⑷化合物9與二乙基甲氣基甲硼烷和NaBH4於酵-有 機溶劑混液中反應並令以矽膠柱層析可得化合物(I) (R4為低烷基)β反應於-100至20 °C,較佳為於-85至 -7 0 °C冷卻下,進行1 0分鐘至5小時,較佳為3 0分鐘至2 小時。 此處,醇包括甲醇,乙酵,丙醇,和丁酵;且有機溶 劑包括同於步驟⑶中者。 此外,視需要,所得化合物可令以與金屬氫氣化物溶 液(R4 :陽離子)進行皂化作用,且於皂化作用後, 反應混液以酸中和並以有機溶劑萃取(R4 :氫)。皂 化作用於一般溶剤如水,乙腈,二鸣烷,丙酮,及其混 液,較佳於齡存在中以習知方法進行〇反應於0至50 °C ,較佳在近室溫下進行。 至於金屬氫氣化物可使用氫氣化納,氫氣化鉀,及其 類似物。 可使用之酸包括無機酸如鹽酸,硫酸等》 (請先閲讀背面之注意事項再填寫本頁) 經濟部屮央標準局貝工消费合作社印製
其中C·,黏線,R 1 , R 2 , R3,和R4各同上定義。 此外,視需要,所得化合物(I)令於加熱下迴流可得 太张Rm Ψ aa因宏Itm(CNS)姒格(2〗0X297公贷) 經濟部屮央標準局貝工消费合作社印製 k,0304^ Λ 6 _Π6_ 五、發明説明(b ) 對應的内酯。 本發明化合物可經口或非經腸投予。例如,本發明化 合物可以錠劑,粉末,膠囊,和顆粒,水狀或油狀懸浮 液之型式,或液態型式如糖漿或酏劑經口投予,及以水 狀或油狀懸浮液之型式非經腸投予。 這些製劑可藉由使用賦形藥,結合劑,潤滑劑,水狀 或油狀安定劑,乳化劑,懸浮劑等以習知方法製備β且 可再使用防腐劑和保存劑》 劑量可視投予途徑,患者年齡,重量,情況,和疾病 種類而異,但通常經口途徑為0.5-200 ng/天,較佳為 l-100mg/天,和非經賜途徑為O.l-lOOmg/天,較佳為 0.5-5〇11^/天。其可使用為單一或分開劑量。 本發明將由下列實施例和參考例颺明,但其並不欲偈 限。 實施例和參考例中所用之縮寫意義如下。 Me:甲基,Et:乙基,i-Pr:異丙基 t-Bu :第三丁基,Ph :苯基, DMF:二甲基甲醯胺,THF:四氫呋喃 DDQ: 2,3-二氣-5, 6-二氰基-1, 4-苯駢酵 TPAP :過釕酸四丙基銨 HMPA :六甲基磷醯胺 DI BAL-H :氫化二異丁鋁 參考例1 (請先閲讀背面之注意事項再填寫本頁) k,0304d Λ 6 B 6 五、發明説明(7 4-(4-氟苯基)-6-異丙基-2-甲硫嘧啶-5-羧酸乙酯 (01-1)和4-(4-氟苯基)-6-異丙基-2-甲磺醛嘧啶-5 -羧酸乙酯(ΠΙ - 2 )
F
COOEt F(p)-PhY^yiPrHVN 2 SMe —— COOEt Ρ(ρ)-ΡΗγΛίγϊΡΓ ΝγΝ SMe (1-1) COOEt Πρ〉-ΡΙγΛγίΡΓ N^N SO,Me (1-2) (請先閲-iAs背面之注意事項再塡寫本頁) 經濟部中央標準局貝工消#合作杜印製 對-氟苯醛81.81克同JP未審査專利公報No.61-40272 説明書中掲示之方式反應可得151.0克(産率:86.7% )之化合物丄。其次44.68克化合物丄於65毫升OPA中 之溶液和28.24克s -甲基異脾硫酸氫之混液於1〇〇 T!下攪 拌22小時。反應混液以醚萃取,並依序以飽和碩酸氫納 和水清洗。乾燥有機層,並蒸除溶劑。所得殘渣令以矽 膠柱層析可得26.61克(産率:46.8%)之化合物上。 於所得化合物互在4QQ毫升苯中之溶液加入21.64克 (0 . ϋ 9 5 m m ο 1)之D D Q ,並攪拌3 0分鐘。其次混液令以矽 膠柱層析可得24.31克(産率:91.9%)之化合物(ffl-1) 〇 NMR (CDC 1 3 ) δ : 1.10 (t, J=7, 3H); 1.31 (d, J=7, 6Hz); 2.61 (s, 裝. -3 _ 線. 太镥;? /f Hi m屮W W它找徂(CNS V丨Μ姒枋m (丨乂 297公 k,0304<i Λ 6 13 6 五、發明説明(容) 經濟部屮央榣準局貝工消费合作社印製 3H ); 3 • 18 (七, J = 7 , 1Η) ; 4 . 18 (q , J = 7 , 2 Η ); 7 . 12 (η, 2H );7 .65 (ffl , 2 Η ) 於 13 .28 克( 0 . 0 4 m m ο 1 )化合物 (ID -1 )在氮仿中之溶液 加 入 17 .98克之間-氛遇 苯甲酸, 並 於室溫 下攪 拌。 其 次 依 序 以 硫酸 納 和 飽和碩 酸氬納清洗 。乾燥 溶液 ,並 蒸 除 溶 劑 且 以正 己 烷 清洗可 得1 3 . 9 3克 (産率: 95 . 7% ) 之 化 合 物 (ΠΙ - 2) Ο NMR (CDC1 Ξ 丨) ά r : 1 . 16 ( t,J =7 9 3H) ; 1 .37 (d, J = 7 , 6H ) ;3 . 26 (七 > J = 7 , 1H); 3 . 4 2 (s, 3H); 4.28 ( q , 2H) ;7 . 18 ( * , 2H); 7 .76 (a 9 2H) 考 例 _2^- 化 合 物(m - 1) 之另一 合成法 於 2 0 〇毫克( 0 . 5 9 4 η η ο 1 )化合物! 在5奄 升二 氣甲 院 中 之 溶 液 加入 0 . 5 克(6.1 〇當量) 之硪酸酐鉀和1 66毫 克 ( 1 . 1當量)之碘, 並於室溫下攪 拌2 .5小時 。反 ate *gSU 歴俟 9 加 入 飽 和 亞硫 酸 £ 納並以 醚萃取。 有 機層以 水清 洗並 乾 燥 〇 減 壓 蒸除 溶 劑 可得1 6 6毫克( 産率:83. 6% ) 之化合 物 (π I - 1), 為 樹 脂物質 〇 NMR (CD C 1 a ) <5 1 . 10 (t , 3H , J =7) ; 1 .31 (d , 6H ,J = 7 ) ;2 · 61 ( S , 3H); 3 .17 (七峰,1H , J = 7 ); 4.1 8 (q . 2H , J = 7) ; 7.07-7.17 (η, 2Η) ; 7.61-7.69 (m, 2 Η) -1 Ο- (請先閲讀背面之注意事項再填寫本頁) 〇3〇^- Λ 6 B 6 五、發明説明(9 ) 兹者例3 化合物(ΙΠ-2)之另一合成法 於1.0克(2.97dibio1)化合物兰在10毫升丙_中之溶液 加入1.5克(9.48ΒΠ101)高錳酸鉀,並於室溫下攪拌15分 鐘。加入1.0毫升醋酸,並於室溫下再攪拌30分鐘且加 入水。反應混液以醚萃取,以飽和碩酸Μ銷和飽和鹽水 清洗並以無水硫酸鎂乾燥。減壓蒸除溶劑可得1.07克 (2.94mmol)(産率:99.1%)之化合物(m-2),為結 晶〇 參考例4 4-(4-氟苯基)-6-異丙基-2-(N-甲基-N-甲磺醯胺 基)嘧啶-5-羧酸乙酯(ΠΙ-3)和4- (4 -氟苯基)-6 -異丙 基-2-(N-甲基-N-二甲基胺磺醯胺基)嘧啶-5-羧酸乙 酯(ΠΙ -4) (1-2) COOEt F( p) -Phv^L/iPr N^N NHMe S_ COOEt F" (p) -Ph^^^iPr
Me (瓜-3) (請先閱讀背面之注意事項再填寫本頁) 裝· '可_ \ 經濟部中央標準局貝工消费合作社印製 -11 COOEt F (p) S02NMe2 (1-4) k,0304d Λ 6 136 五、發明説明(I。) 於 5 2 . 7克(1 44 〇 1 )化合物(ΠΙ -2 )在 5 0 0毫 升 绝對酒精 中 之 溶液 在冰 冷 卻下 缓慢加入71 .9¾升5N甲 基 胺/乙酵 溶 液 〇反 應混 液 溫熱 至室溫,1» 拌1小時並 減 壓蒸發》 於 殘 渣中 加入 水 ,並 以醚萃取, 乾燥並減壓 蒸 發可得 4 6 .9克( 産率 : 1 0 0 % )之化合物立。 熔點85- 8 6eC Civ Η 20 Ν Ξ )F 0 2 :分析計算值: C , 6 4 . 34 ; Η , 6.35; Ν , 1 3.24; F, 5.99 實 «Α|| 測 值: C , 6 4 . 42 ; Η , 6.46; Ν , 1 3.30; F, 6.14 於 3 7 0毫克( 1 . 2 13· Β 0 1 )化合物 立在5 毫升 DMF中之溶 液 在 冰冷 卻下 加 入60 毫克60 % Na H,並 攪拌30分鐘。加 入 208毫克之甲磺醯氣,並將混液粗熱 至室溫且再攪拌 2 小 時。 加入 冰 水, 並以醚萃取 混液。 有機 層 以水淸洗 並 乾 燥〇 減驪 蒸 除溶 剤,並以醚 -正戊 烷清洗所得殘渣 可 得 3 2 2毫克 (産率: 5 7 . 6 % )之化合 物(m -3 )〇 NNR (CDC 1 3 ) δ : 1 . 10 (t , J = 7 9 3Η); 1.32 ( d , J = 7, 6H); 3 . 24 (七, J = 7 , 1H) ;3 . 52 (s, 3H); 3.60 (s , 3H); 4 . 19 (q, J = 7 , 2H) ;7. 14 (, 2 Η) ; 7.68 (爾, 2H) (請先閲讀背面之注意事項再填寫本頁) 經濟部中央櫺準局貝工消费合作社印製 於4.13克(13.0|»»〇1)化合物3在40毫升0»^中之溶液 在冰冷卻下加入〇 . 5 7克6 0 % fi a Η ,並將混液溫熱至室溫 且攪拌1小時。再度冷卻後,滴加入2.43克(16.9|〇1«〇1) 二甲基胺磺醯氰,並擻拌2.5小時β加入冰水,並以醚 萃取混液,以水淸洗,乾燥並滅壓蒸發以臃出醚。所得 -1 2- 03044 Λ 6 Β6 五、發明説明(" 殘 渣 以 m -己烷淸洗可得 4 · 1 0克( 産率: 74 .2 % ) 之 化 合 物 (III - 4 ) β熔 點1 1 4-1 1 6°C C 19 Η 7Β N , ! S F0 4 分析 計算值: C , 5 3 . 76 ; Η , 5.94; N , 13 • 20 ;F , 4 . 48 實 测 值 : C , 5 3 . 74 ; Η , 5.96; N , 13 .19 ;F , 4 . 78 參 考 例 5 4 - ( 4- 氟苯基 )-6 -異 丙基-2-甲氧 哺 旋_ 5-羧酸 乙 酯 (ΠΙ - 5 )和 4 - ( 4 - 氟苯 基) -6-異丙 基- 2- (N _甲基- N- 甲 磺 酵 m 基 )嘧啶 -5-羧酸 乙酯(ΠΙ - 6) COOEt F (p) -Phs/^y iPr (請先閱讀背面之注意事項再塡寫本頁) (1-2)
OMe (1-5) 裝·
-線‘ 經濟部中央標準局员工消费合作社印製 !Me. (1-6) 於1.39克(3.8mmol)化合物(m - 2)在60毫升絶對酒精 中之溶液在冰冷卻下加入0.41克(7.6 ranol)甲酵納溶液 。反應混液缓慢溫熱至室溫並攪拌1小時β混液以醋酸 中和並以醚萃取。有機層依序以重硪酸納和水清洗,乾 燥並減壓蒸發以皤出醚。殘渣令以矽膠柱層析可得1.17 克(産率:96.7%)之化合物(ΙΠ-5)。 13- 太皈张尺泞这丨fl屮闽《犮找谁(〇^)屮4)«格(21〇乂^7公1)
五、發明説明(ι>) N M R (CDC1 3 ) δ : 1.10 (t , 3Η, J=7Hz); 1.32 (d, 6H, J=6.6 Hz ); 3.21 (B, 1H); 4.08 (s, 3H);4.18 (q, 2H, J = 7 經濟部中央標準局貝工消費合作社印製 7.07-7.74 (η, 4Η) 於2· 50克(6 .77^01 )化合物(Μ -2)在50毫升绝對酒精 中之溶液在冰冷卻下加入〇·80克(16.93βιβο1)之甲肼。 反應混液溫熱至室溫並攪拌2小時且以#萃取。有棟層 以飽和鹽水清洗並乾燥以皤出溶劑》2.37克所得化合物 和無水THF和無水吡啶之混液,在冰冷卻下加入丨.03克 (7.84bb〇1)之甲磺醛《。反應混液溫熱至室溫並攪样 1.5小時。加入3毫升無水吡啶和1.53克(11.65β·ο1)之 甲磺醛氣,並攛拌2小時。於反應混液中加入冰水並以 継萃取β有機層以水清洗且所得油狀殘渣令以矽睡柱層 析可得2.75克(産率:94.0%)之化合物(瓜_6)〇 NMR (CDC 1 a ) S : 1.08 (t , J = 7, 3 Η) ; 1.29 (d, J = 7, 6 Η ) ; 2.96 (s, 3 Η) ; 3.24 (t , J = 7, 1 Η) ; 3.59 (s, 3Η) ; 4.16 (q , J=7, 2H); 7.14 (ι, 2H); 7.63 (ffl, 2Η) 參考例6 (3R)-3-(第三丁基二甲基甲矽烷氣基)_5_氣基_6_ 三苯磷丙琛叉己酸甲酯 ⑴(3R)-3-(第三丁基二甲基甲矽烷氣基 > 戊二酸_1_ ((R)-(-)-苯乙酵酸酯·165克溶入60毫升甲酵,於〇 ·〇 -1 4 - (請先閱讀背面之注意事項再填寫本頁) 裝· Λ 6 Β 6 經濟部中央標準局貝工消f合作社印製 五、發明説明(0) 氮 氣 内 部 溫度7 °c 下歴 45分鐘滴加 入 甲酵 納於 甲 酵(28 % 甲 醇 3 1 〇毫升, 1 .6契 耳)中之溶 液 〇反 應混 液 於0 °c m 拌 30分 鐘並於 冰 冷卻 下倒入150毫升濃HC1, 30 10毫升 水 , 和 50 0毫升二氣甲烷之混液且收集有機層。 水層以 2 0 〇毫升二氛甲烷萃取, 且各有機層依序以稀HC1和鹽水 清 洗 〇 收 集各有 機 層並 以無水硫酸 Ιϋ 乾燥 且蒸 發 以皤出 溶 劑 可 得 半酯化 合 物。 1 HNMR (CDC1a ) δ : 0 . 08 (S, 3H); 0 . 09 (s, 3Η) ; 0 . 86 (s , 9H) ; 2.52- 2 . 7 3 ( 1B , 4H); 3 . 08 (s,3Η) ; 4 . 55 (五 ,1H 9 J=6 Hz) IR (CHC1 a ):2880 ,17 34 , 17 12, 14 38 , 1305 9 1 0 9 6 , 8 3 6 cm·1 [α ] D :— 5 . 0 ± 0 .4 ° (C = 1.0 4 , 2 3 . 5°C , CHC 1 a 丨) Rf 0 .3 2 (CHC1Ξ ,/MeOH = 9/1) » 1 : 此 化合物 可 依公 開 2-250852說 明書 第10 頁 所述方 法 製備》 ⑵ 於 所 得半酯 化 合物 在1 〇毫升_ 中 之溶 液, 在 -78°C 氮 氣 下 依 序滴入 三 乙胺 和氛羧酸乙 酯 〇所 得白 色 懸浮液 於 〇 °c下攪拌1小時並冷卻至-7 8 °C 0 於氮 氣下 過 濾所得 沉 澱 物 並 以15毫 升 醚清 洗過濾物。 於 1 · 2 9克 < 3 .6 B 0 0 1 ) 甲 基 溴 三 苯燐在 5 毫升 T H F中之溶液, 在_ 7 8°C m 氣下滴 加 入 丁 基 鋰(1 · 6M已烷 ,2 . 25毫升 * 3 . 6 mmol ) β反應 混 液 於 〇 °c下攪拌1小時 並冷卻至-7 8 eC且滴加入所得活 -15- (請先閱讀背面之注意事項再填寫本頁) ,0304^ 經濟部中央標準局Μ工消t合作社印製 Λ 6 _Π6_ 五、發明説明(,々) 性酯化合物於醚中之溶液《反應混液以5毫升THF清洗 並在〇°C下攪拌1小時,且加入10毫升之5%碩酸氫納。 反應混液攪拌5分鐘並以乙酸乙酯萃取且分離有機層並 以乙酸乙酯萃取剩餘的水層。收集各有機層並以鹽水清 洗,以無水硫酸鎂乾燥並瀝縮。所得殘渣令以矽醪柱層 析,以醚-乙酸乙酯溶離並自K -己烷結晶可得標的化合 物〇 1 HNMR ( C D C 1 a ) δ : 0.04 (s , 3Η) ; 0.06 (s , 3Η) ; 0.83 (s, 9H); 2.4- 2.9 (m, 4H); 3.64 (s, 3H); 3.74 (d, 1H), 4.5-4.7 (ai, 1H); 7.4-7.8 (η, 15H) IR (CHC1 a ) : 2 8 8 0 , 1 7 3 0, 1 5 2 8 , 1 4 3 7 , 1 2 5 0, 1 1 0 6 , 8 3 5 c a [a ] D =-6.2° ( C = 1 . 2 7 , 22.0。。,CHC 1 3 )熔點:77.5-78.5 °C, Rf = 0 . 48 ( CHC 1 a /MeOH = 9/l ) C 31 fl 39 0 4 P S分析計算值: C , 6 9 . 6 3; Η , 7.35; P , 5.79 實測值:C,6 9 . 3 5 ; H,7 . 3 5 ; P,6 . 0 9 實施例1 ( + )- 7-〔4- (4-氟苯基)-6-異丙基-2- (N-甲基- N-甲磺醛胺嘧啶)-5-基〕-(3R, 5S)-二羥基-(E)-6-庚烯 酸納(la-1)-1 6 - (請先閲讀背面之注意事項再填寫本頁) 裝- '線- /i Λ 6 ΰ 6 五、發明説明(八) ⑴於322毫克之參考例2所得化合物(ΙΠ-3)在7毫升無 水甲苯中之溶液,在- 74°C滴加人1.4毫升之DIBAL-H/ 1.5M甲苯,反應混液攪拌1小時並加入醋酸。以_萃取 混液,並以重硪酸納和水清洗有機層,乾燥並減壓蒸發 以餾出醚。所得殘渣令以矽膠柱層析,以二氛甲烷/醚 (20/1)溶離可得277毫克(産率:96.1%)之〔4- (4-氟苯基)-6-異丙基-2-(N-甲基-N-甲磺醯胺基)嘧啶-5-基〕甲醇4 。
CH3O2S
Ph-F(p)
2 OH 4_ ⑵將277毫克所得化合物号,190¾克4-甲基嗎福啉-H-氣化物,6毫克TPAP, 1.0克粉末分子篩4A,和10毫升 二氯甲烷之懸浮液攪拌2小時。濾除不溶物並於減壓下 蒸除2/3之過濾物。所得殘渣令以矽謬柱層析,以二氯 甲烷溶雔可得196毫克(産率:71.2%)之4- (4-氣苯 基)-6-異丙基-2-(N-甲基-N-甲磺酵胺基)-5-嘧啶醛 ,為結晶。 (請先閱讀背面之注意事項再填寫本頁) 裝. ,?T_ 線- 經濟部中央標準局员工消t合作社印製
CH3 CH3O2S >
Ph-F(p) CHO iPr
17- 5_ Λ 6 Μ 6 五、發明説明(,b) ⑶190毫克化合物§,450毫克(3R)-3-(第三丁基二 甲基甲矽烷«基)-5-氣基-6-三苯磷丙琛叉己酸甲酯( 參考例6 ),和5毫升乙腈之溶液於加熱下迴流1 4小時 並減壓蒸發以皤出乙腈。所得殘渣令以矽醪柱層析,以 二氮甲烷溶離可得233毫克(産率:71.3%)之7-〔4-(4-氟苯基)-6-異丙基-2-(N-甲基-N-甲磺醯胺基) 嘧啶-5-基〕-(3R)-3-(第三丁基二甲基甲矽烷氣基)-5-氣基-(E)-6-庚烯酸甲酯,為漿狀。
CH3 CH3O2S
_6_ (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局貝工消費合作社印製 ⑷於16克化合物§在100毫升乙腈中之溶液,在冰冷 卻下滴加入48%氟化氫於400毫升乙腈(1: 19)中之溶液 ,並將混液溫熱至室溫並攪拌1.5小時。反應混液以重 碩酸納中和並以醚萃取。有機層以氛化納清洗,乾燥並 減鼷蒸發以皤出醚,可得13克(産率:100%)之7-[ 4-(4-氟苯基)-6-異丙基-2-(N-甲基-N-甲磺醛胺基 )嘧啶-5 -基〕-(3 R) - 3 -羥基-5 -氣基-(E ) - 6 -庚烯酸甲 酯7 ,為漿狀。
L 太张R浼iA m M W玄找谉(CNS) 格(210 X 297公帒) 經濟部中央標準局貝工消费合作社印製 Λ 6 Β 6_ 五、發明説明(Ο) ⑸於13克化合物[在350毫升無水THF和90毫升甲酵中 之溶液,在-78 °C下加入29.7毫升1M二乙基甲氣甲硼烷-THF溶液,並在相同溫度下攪拌30分鐘。加入1.3克NaBH4 ,並褪拌3小時。加入16毫升醋酸,並以飽和的重磺酸 鈉讁整至PH 8且以醚萃取。有機層以水清洗,乾燥並減 壓蒸除醚。於所得殘渣中加入甲醇並減壓蒸發混液三次 。所得殘渣令以矽膠柱層析,以二氣甲烷/醚(3/1)溶 離可得11.4克(産率:85.2%)之7-〔4- (4-氟苯基) -6-異丙基-2-(N-甲基-H-甲磺醯胺基)嘧啶-5-基〕-(3R, 5S)-二羥基-(E)-6-庚烯酸甲酯,為漿狀。 (請先閲讀背面之注意事項再填寫本頁) 呷 0H Ph-F(p)
:00Me (Ib-1) NMR (CDC1 a ) δ : 1.27 (d, J=7, 6H); 1.53 (m, 2H); 2.47 (d, J=6, 2H); 3.36 (七,J=2H); 3.52 (s, 3H); 3.57 (s, 3H) ;3.73 (s, 3H); 4.20 ( id , 1H); 4.43 (m , 1H); 5.45 (dd, J=5, 16, 1H); 6.64 (dd, J=2, 16, 1H); 7.09 (η , 2H) ; 7.64 (η , 2H) ⑹於11.4克化合物(Ib-1)在160毫升乙酵中之溶液, 在冰冷卻下加入223毫升之0.1 N氫氣化納6反應混液溫 熱至室溫並檐拌1小時。減壓蒸除溶爾,並於所得殘渣 -1 9 -
CH3〇2S ^〇3〇^- Λ 6 Β 6 五、發明説明(I?) 中加入醚且攙拌混液可得11.0克(産率:95.0%)之標 的化合物(la-1),為粉狀結晶。
經濟部中央標準局爲工消費合作杜印製 [α ] D =+ 1 8 . 9 士 0 .6° ( C= 1 .012 ,25 .0°C , Η 2 〇) NMR (CDC 1 3 )^ : 1 . 24 (d, J = 7 , 6H) ; 1 .48 (, 1H) ;1.65 (m , 1H ); 2 . 27 (dd, J =2 , 6 . 2H) ;3 .4 1 (七, J = 7 , 1H); 3 . 48 (s 9 3H); 3 . 5 9 ( s , 3 Η ); 3.73 (確, 1H); 4.32 (a » 1Η); 5.49 (dd , J = 7 , 1 6 , 1H) ;6 · 62 (d , J= 1 6 9 1H); 7 . 19 (ffl , 2H ); 7 .56 ( m , 2 H) 實 施 例2 (+ )-7- 〔4 -( 4 -氟苯 基) -6 - 異丙 基-2 - "-乙 m 基-N -甲胺基) 嘧 啶- 5 -基〕 (3R ,5S )-二 羥基-( E ) - 6 - 庚 烯酸 納 (I a - 2 ) ⑴ 令838 毫 克參 考例4 :所 得之 4-( 4-氟苯 基)- 6 - 異丙 基 -2 -甲胺 嘧 啶- 5 -羧酸 乙酯3同實施例1⑴和⑵ 之 方式 反 應 可得1 57 毫克 之4 - (4- 氟苯 基) -6-異丙基-2 -甲胺 哺 啶 _ 5 -碎 〇 ⑵ 1 5 7* 克 由此 所得之醛 化合 物於 4毫升 無水DMF中之 溶 液 ,在冰冷卻 下與25 毫克之6 0% N aH反應 30分鐘, 加 -20- 太ifr 尺泞 ili Ifl Φ W W 玄找m i CNS) ¥ 4 W格(2 m X 297公.修) (請先閲讀背面之注意事項再填寫本頁) ,〇3〇的 Λ 6 Β6 五、發明説明((9) 入〇·〇5毫升之乙酷氯並攪拌1小時。混液中加冰並以醚 萃取。有機層以水清洗並乾燥濃縮以餾出溶劑,可得 167毫克(産率:93.4%)之4- (4-氟苯基)-6-異丙基 -2- (Ν -乙酵基-Ν-甲胺基)嘧啶-5-醛。所得之g化合 物同實施例1⑶-⑸之方式反應可得7 -〔 4 - ( 4 -氟苯基 )-6 -異丙基-2- (N -乙酵基-N-甲肢哦淀)-5 -基〕-(3R ,5S)-二羥基-(E)-6-庚烯酸甲酯(Ib-2)e NMR ( CD C1 a ) S : 1.27 (d, J=7, 6H); 1.54 (m, 2H); 2.48 (d, J=6, 2H); 2.52 (s, 3B);3.39 (± , J=7, 1H); 3.60 (s, 3H); 3.58 (brs, 1H); 3.74 (s, 3H); 4.21 (m, 1H); 4.48 (a, 1H); 5.50 (dd, J=5, 16, 1H); 6.66 (dd, J=2, 16); 7.11 (b, 2H); 7.61 (m, 2H) ⑶所得化合物(I b - 2 )同S施例1⑹之方式反應可得標 的化合物Ua-2)。
(請先閱讀背面之注意事項再填窝本頁) 裝· 訂- -線< 經濟部中央標準局貝工消费合作杜印製 (I a-2) NMR (CDC1 3 ) δ : 1.27 (d, J = 7 , 6Η); 1.57 (η , 2Η); 2.17 (s , 2.27 (d, J = 6 , 2Η); 3.72 (s , 3Η); 3.50 (t , 1Η); 3.70 ( η , 1Η); 4.35 (q, J = 6 , 1Η); 5.59 2 1 以)3_ Λ 6 B6 五、發明説明(>D) J=5.16, 1H); 6.54 (d, J=16, 1H); 7.24 (a, 2H); 7.59 (a , 2H) 實施例3-6 參考例1-3中所得之各喃啶羧酸酯(ffl )做為起始物質 ,同實施例1或2之方式反應可得化合物(lb)和(Ia)e 其物理常數示於表1-3»
Ph-F(p) :OOEt
Me-Xx^brNiPr (I)
(lb)
(la) (請先閱讀背面之注意事項再塡寫本頁) 裝- 線· 經濟部中央標準局员工消費合作社印製 -22- ο 3 ο G C Λ: 五、發明説明(>|) 經濟部中央橾準局员工消費合作社印製 表 1 實施例 No. 起始物質 産物 NMR δ1 3 (1-1) I b-3 (X: S)産率 96.0% (CDC1S) 1.26 (d, J=7,6H); 1.52 (m, 2H); 2.47 (d,J=6, 2 H); 2.60 (s, 3H); 3.33 (七:,J=7,1H); 3.73 ( s, 3H); 4.18 (m, 1H); 4.44 (m, 1H); 5.44 (dd, J=5,16,1H); 6.60 (dd, J=2,16, 1H); 7.07 (m, 2H );7.58 (m, 2H) Ia-3(X: S)産率 87.3% (D,0) 1.20 (d, J=7, 6H); 1.47 (m, 1H); 1.61 (m, 1H); 2.26 (m, 2H); 2.54 (s, 3H); 3.36 (七,J=7,1H );3.71 (m, 1H); 4.29 (m, 1H); 5.43 (dd, J=6,l 6, 1H); 6.55 (d, J=16,1H); 7.16 (m, 2H); 7.47 (ο, 2H) 4 (1-2) Ib-4 (LSO:):産率 93.7% (CDC1,) l. 31 (d, J=7, 6H); 1.52 (m, 2H); 2.A8 (d, J=6, 2H); 3.40 (s, 3H); 3.47 (七,J=7, 1H); 3.74 (s, 3H); 3.87 (brs, 1H); 4.23 (m, 1H); 4.49 ( m, 1H); 5.59 (d,d, J=5,16H, 1H); 6.74 (d,d,J= 2,16, 1H); 7.12 (m, 2H); 7.69 (m, 2H) la-4 (X:S0,):産率 70.9% (DW) 1.27 (d, d, J=7,2,6H); 1.60 (m, 2H); 2.25 (J= 6, d, 2H); 3.44 (s, 3H); 3_51 (七,J=7, 1H); 3.70 (m, 1H); 4.33 (q, J=6,1H); 5.65 (d,d,J=5, 16, 1H); 6.71 (d, J=16,1H); 7.23 (m, 2H); 7.60 7.60 (m, 2H) -23- 本紙张尺度边用中《國家梂準(CNS)甲4規格(210X297公址) (請先閲面之注意事項再填寫本頁) 裝. 線·
i·1 : Λ G Π (i 五、發明説明 經濟部中央櫺準局貝工消费合作社印31 表 2 f施例 起始物質 産物 No. NMR S I b-5 (X:0): (CDC1S) 1.27 (d, 6H, J=6.6Hz); 1.35-1.68 (m, 2H); 2.47 5 (1-5) (m, 2H); 3.34 (m, 1H); 3.78 (s, 3H); 4.03 (s, 3H); 4.19 (m, 1H); 4.43 (m, 1H); 5.43 (dd, 1H, J=5.6,16Hz); 6.59 (dd, 1H, J=1.4, 16Hz); 7.03-7.64 (m, 4H) la-5 (X: 0):産率 57.7% (CDC1S,CD,0D) 1.27 (d, 6H, J=6.6Hz); 1.35-1.68 (m, 2H); 2.17 -2.43 (m, 2H); 3.36 (m, 2H); 4.05 (s, 3H); 4.3 7 (m, 2H); 5.A8 (dd, 1H,J=5.6,16Hz); 6.54 (dd, 1H, J=1.4,16Hz); 7.06-7.65 (m, 4H) * I b-6 (X:N-S0,NMet) : (CDC1S) 1.26 (d, 6H, J=6.6Hz); 1.38-1.62 (ra, 2H); 2.47 6 (1-4) (d, 2H, J=5.8); 2.84 (s, 6H); 3.35 (m, 1H); 3.64 (s, 3H); 3.74 (s, 3H); 4.20 (m, 1H); 4.4Λ (ra, 1H); 5.42 (dd, 1H, J=5.4, 16Hz); 6.60 (dd,lH, J=1.2,16Hz); 7.03-7.64 (m, 4H) la-6:産率 91.2% (CDC1” CD,〇D) 1.26 (d, 6H, J=6.6Hz); 1.36-1.69 (m, 2H);2.15-2.50 (m, 2H); 2.85 (s, 6H); 3 .41 (m, 2H); 3.6 4 (s, 3H); 4.04 (m, 1H); 4.37 (m, 1H); 5.A8 ( dd, 1H, J-5.6,16Hz); 6.54 (dd, 1H, J-l,16Hz); 7.05-7.66 (m, 4H) -24- (請先閱讀背面之注意事項再堺寫本頁) 裝- 、町. 線- 本紙张尺度边用中a B家標準(CNS) τ 4規格(210 X 297公放)
66 Λ,Γ 五、發明説明(>士) 表 3 Γ 贲施例 No.
起始物質 産物 NMR S (1-6) I b-7 (X:N-NHSOaMe):産率:87.8% (CDC1,) 1.24 (d, J=7,6H); 1.51 (m, 2H); 2.47 (d, J=6, 2H); 2.95 (s, 3H); 3.35 ( t , J=7,1H); 3.46 ( d, J=2,1H); 3.55 (s, 3H); 3.66 (d,J=2,lH); 3.7 4 (s, 3H); 4.18 (ra, 1H); 4.44 (m, 1H); 5.41 (d d, J=5,16, 1H); 6.58 (dd, J=2,16, 1H); 7.09 (m ,2H); 7.58 (ra, 2H); 7.70 (s, 1H) la-7 (XiN-NHSOWe):産率:74.7%(D20) 1.23 (d, J=7,6H); 1.51 (m, 2H); 2.26 (d, J=6,2 H); 3.10 (s, 3H); 3_37 (七,J=7,1H); 3.4Λ ( s, 3H); 3.70 (ra, 1H); 4.29 (q, J=6, 1H); 5.39 (dd, J=5,16, 1H); 6.58 (d, J=16, 1H); 7.19 (m, 2H); 7.52 (m, 2H) (請先閱讀背而之注意事項再项寫本頁) 經濟部中央席準tycy1·消玢咋fi印" -25- 本紙張尺度边用中a國家櫺準(CNS)肀4規格(210X297公址) Λ 6 13 6 經濟部中央標準局負工消费合作杜印製 五、發明説明()4·) 實施例7 ' 化合物(Ia-Ι)之鈣鹽 化合物(Ia-Ι)(納鹽)1.50克(3.00mffl〇l)溶入15豪 升水中並於氮氣室溫下攪拌,歷3分鐘連缠滴加入3.00 毫升(3.0Qmn〇l)之1莫耳/升氣化納。反應混液於相同 溫度下攪拌2小時,並收集所得沉澱物,以水清洗並乾 燥可得1.32克之鈣鹽,為粉狀。此化合物在155 °C溫度 下開始融解,但明確的熔點仍為含糊不定。 [ct]d= + 6.3±0.2° (C = 2.011, 25.0 0C, MeOH) CnHnh 06 SF· 0.5Ca· 0.5 H2 0分析計算值: C, 51,85; Η, 5.53; 0, 8.25; F, 3·73; C a , 3.93 實測值:C, 51.65; H, 5.51; N, 8.47; F, 3.74; Ca , 4.07 牛物沃袢 試驗 HMG-Co A還原酶抑制功效 ⑴鼠肝臓橄粒睡之製備 使用S p r a g u e - D a w 1 e y鼠(其為己自由使用含有2 J!雎固 醇胺之一般飲食和水2遇)以製備鼠肝臓撤粒體。此所 得撤粒體依 Kuroda等人,Biochen. Biophys. Act, 486 ,70 (1977)之方法精製。於105000xg離心所得之撤粒 體分劏以含有1 5 Μ菘鹺醯胺和2 Μ氮化鎂之缓衝溶液( 2 6- (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局貝工消费合作社印製 五、發明説明(>上) 於100 mM磷酸狎级衡液中,PH 7.4)清洗一次。以同於 所使用肝臓重量之含有菸_醏胺和氣化鎂之緩衝液均質 化。冷卻此均質物並保存於-8 Q°C。 ⑵Η M G - C ο A還原酶抑制活性之測定 保存於- 80°C之鼠肝臓撤粒體樣品(100^1)在〇°C下 融化並以0.7毫升冰磷酸鉀緩衝液(IOObM, pH 7.4)稀 釋。其與0.8毫升之5QmM EDTA (以前述之磷酸押缓衝液 缓衝)和0.4毫升之lOOmM二硫蘚糖酵溶液(以前述之磷 酸鉀緩衝液缓衝)混合,並將混液保存於Q °C。撖粒龌 溶液( 1.675毫升)混以670/il之25 biM NADPH(以前述 之磷酸鉀緩衝液緩衝),並將其加至0·5βΜ [3_ 14C] HMG-CoA (3BCi/BB〇l)之溶液中。將受試化合物之納鹽 溶入磷酸鉀缓衝液中之溶液(5>u 1)加至45# 1之混液中 。所得混液在37°C下培養30分鐘並冷卻。於加入10# 1 2N-HC1終止反應後,混液再於37°C下培養15分鐘並將30 A 1之混液令以厚度為〇.5ub之矽膠薄層層析(Merck AG, Art 5744)。層析以甲苯/丙酮(1/1)展開,並刮下Rf值 於0.45至G.60間之點。將所得物置入含有1〇毫升閃爍剤 之小瓶中,以閃燦計數器測定比放射活性。本化合物之 活性7F於表4 ,其為比較以假設參考藥物Mevinolin ( 納鹽)之活性為1 0 0者。 (請先閱讀背面之注意事項再塡寫本頁) -27- 太紙帒Η泞ΐΛ丨11屮闽囚玄找S (CNS) m权m 0 乂 297公修) %0咖/! Λ 6 Β 6 五、發明説明〇b) 表 受試化合物 暹原酶抑制活性 I a- 1 4 4 2 I a- 3 385 I a- 5 2 7 9 la-7 2 6 0 Mevinolin N a 10 0 由此試驗數據,本發明化合物具有優於Mevinolin之 HMG-CoA邇原酶抑制活性。 (請先閲讀背面之注意事項再填寫本頁) 裝· 訂. 線 經濟部屮央標準局貝工消t合作社印製 -28-
Claims (1)
- 81.12. 2f斗η A7 笮7 卞 六、申請專利範園 第81105115號「嘧啶衍生物」專利案 (82年2月修正) 1. 一種如式(I)之化合物,或其對應的閉琛内酯: OH 0Η00R' 烴濟部中央標準局3工消費合作社印製 其中 C 1 C 1 X為 ;點 2 .如申 3 .如申 4 ·如申 5 .如申 被烷 取代 6 .如申 光學 7 .—種 以申 R1為匚丄-β院基;Ra和R3各自為氫, -β烷基,或任意被取代苯基;R4為氫, -3烷基,或可形成無毒製蕖容許鹽之陽離子; 硫,氣,或磺醛基,或亞胺基其可具有一取代基 線代表雙鍵之有或無。 請專利範園第1項之化合物 誚專利範圍第1項之化合物 請專利範園第1項之化合物 請專利範圍第1項之化合物 其中X為硫。 其中X為氣。 其中X為磺醯基。 其中X為亞胺基可 磺醯基,烷羰基,烷磺醛胺基或二烷胺磺醯基所 〇 請專利範圔第1項之化合物,其中該化合物為以 活性型式。 作為HMG-CoA還原酶抑制劑之醫蕖組合物,包括 請專利範圍第1項之化合物做為活性成分。 本蛾张又茂適用家棣準(CNS)甲4規格(210 X 297 ) -----------------(-------裝------.玎-----一.-^- (請先閲讀背面之注免事項再塡寫本頁)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP18801591 | 1991-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW203044B true TW203044B (zh) | 1993-04-01 |
Family
ID=16216169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW081105115A TW203044B (zh) | 1991-07-01 | 1992-06-29 |
Country Status (19)
Country | Link |
---|---|
US (2) | US5260440A (zh) |
EP (1) | EP0521471B1 (zh) |
JP (1) | JP2648897B2 (zh) |
KR (1) | KR960005951B1 (zh) |
AT (1) | ATE197149T1 (zh) |
CA (1) | CA2072945C (zh) |
CL (1) | CL2010000113A1 (zh) |
CY (2) | CY2226B1 (zh) |
DE (2) | DE69231530T2 (zh) |
DK (1) | DK0521471T3 (zh) |
ES (1) | ES2153824T3 (zh) |
GE (1) | GEP20022693B (zh) |
GR (1) | GR3035189T3 (zh) |
HK (1) | HK1011986A1 (zh) |
HU (2) | HU219407B (zh) |
LU (1) | LU91042I2 (zh) |
NL (1) | NL300125I2 (zh) |
PT (1) | PT521471E (zh) |
TW (1) | TW203044B (zh) |
Families Citing this family (380)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677455A (en) | 1994-09-06 | 1997-10-14 | Ube Industries, Ltd. | Preparation of 3-oxy-5-oxo-6-heptenoic acid derivatives |
TW440563B (en) * | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
US5952331A (en) * | 1996-05-23 | 1999-09-14 | Syntex (Usa) Inc. | Aryl pyrimidine derivatives |
US5958934A (en) * | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
GB9900339D0 (en) * | 1999-01-09 | 1999-02-24 | Zeneca Ltd | Chemical compounds |
AR022462A1 (es) * | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
GB0000710D0 (en) * | 1999-02-06 | 2000-03-08 | Zeneca Ltd | Drug combination |
GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
CZ298235B6 (cs) * | 1999-03-10 | 2007-08-01 | Lonza Ag | Zpusob výroby N-[5-(difenylfosfinoylmethyl)-4-(4-fluorfenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethansulfonamidu |
US6160115A (en) * | 1999-03-10 | 2000-12-12 | Lonza Ag | Process for preparing N-[5-(diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin -2-yl]-N-methylmethanesulfonamide |
US6579984B1 (en) * | 1999-07-13 | 2003-06-17 | Lonza Ag | Process for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate |
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
PT1265860E (pt) | 2000-03-24 | 2005-10-31 | Pharmacia Corp | Compostos amidino uteis como inibidores de sintase de oxido nitrico |
AR030414A1 (es) * | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
AR030416A1 (es) | 2000-04-13 | 2003-08-20 | Pharmacia Corp | COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA |
US6956131B2 (en) | 2000-04-13 | 2005-10-18 | Pharmacia Corporation | 2-amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors |
AR032318A1 (es) | 2000-04-13 | 2003-11-05 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa |
US6545170B2 (en) | 2000-04-13 | 2003-04-08 | Pharmacia Corporation | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
US6787668B2 (en) | 2000-04-13 | 2004-09-07 | Pharmacia Corporation | 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
AR034120A1 (es) | 2000-04-13 | 2004-02-04 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico |
GB0011163D0 (en) * | 2000-05-10 | 2000-06-28 | Astrazeneca Ab | Chemical compound |
SE0002354D0 (sv) * | 2000-06-22 | 2000-06-22 | Astrazeneca Ab | New formulation |
EP1320371A2 (en) * | 2000-07-31 | 2003-06-25 | Ottawa Heart Institute Research Corporation | Charged phospholipid compositions and methods for their use |
US6495544B2 (en) | 2000-08-01 | 2002-12-17 | Pharmacia Corporation | Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase |
AU2001284413A1 (en) * | 2000-08-30 | 2002-03-13 | Sankyo Company Limited | Medicinal compositions for preventing or treating heart failure |
AR030741A1 (es) | 2000-09-15 | 2003-09-03 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa |
AR031129A1 (es) | 2000-09-15 | 2003-09-10 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
PL361097A1 (en) * | 2000-10-12 | 2004-09-20 | Nissan Chemical Industries, Ltd. | Preventives and remedies for complications of diabetes |
US6777552B2 (en) | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
GB0028429D0 (en) * | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
KR100883874B1 (ko) | 2001-02-02 | 2009-02-17 | 미쯔비시 가가꾸 가부시끼가이샤 | (3r,5s)-(e)-7-[2-시클로프로필-4-(4-플루오로페닐)-퀴노린-3-일]-3,5-디하이드록시헵트-6-엔산 에스테르류의 제조방법 |
CA2444481A1 (en) | 2001-04-11 | 2002-10-24 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
DK1417180T3 (da) | 2001-07-13 | 2007-04-10 | Astrazeneca Uk Ltd | Fremstilling af aminopyrimidinforbindelser |
US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
KR20040054729A (ko) * | 2001-10-18 | 2004-06-25 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도 |
SE0103509D0 (sv) * | 2001-10-19 | 2001-10-19 | Astrazeneca Ab | Rosuvastatin in pre demented states |
US6984645B2 (en) * | 2001-11-16 | 2006-01-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
US6835838B2 (en) * | 2002-01-28 | 2004-12-28 | Novartis Ag | Process for the manufacture of organic compounds |
WO2003096548A2 (de) * | 2002-05-14 | 2003-11-20 | Siemens Aktiengesellschaft | Verfahren zum erzeugen eines sendesignals |
US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
AR039836A1 (es) * | 2002-05-21 | 2005-03-02 | Ranbaxy Lab Ltd | Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina |
US20050182106A1 (en) * | 2002-07-11 | 2005-08-18 | Sankyo Company, Limited | Medicinal composition for mitigating blood lipid or lowering blood homocysteine |
US20050182036A1 (en) * | 2002-08-02 | 2005-08-18 | Sankyo Company, Limited | Medicinal composition containing an HMG-CoA reductase inhibitor |
US20050187204A1 (en) * | 2002-08-08 | 2005-08-25 | Sankyo Company, Limited | Medicinal composition for lowering blood lipid level |
GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
EP1625223A4 (en) * | 2002-09-20 | 2009-11-11 | Verenium Corp | CHEMOENZYMATIC PROCEDURES FOR SYNTHESIS OF STATINES AND STATIN INTERCONNECTIONS |
US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
ATE469645T1 (de) * | 2002-10-23 | 2010-06-15 | Bristol Myers Squibb Co | Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
HUP0500851A3 (en) | 2002-12-10 | 2008-02-28 | Ranbaxy Lab Ltd | Process for the preparation of rosuvastatin |
CA2509344C (en) | 2002-12-16 | 2011-10-04 | Astrazeneca Uk Limited | Process for the preparation of pyrimidine compounds |
GB0229243D0 (en) * | 2002-12-16 | 2003-01-22 | Avecia Ltd | Compounds and process |
AU2003283769A1 (en) | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
TW200504021A (en) * | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
JP2006516620A (ja) * | 2003-01-24 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | 甲状腺受容体におけるシクロアルキル含有アニリドリガンド |
BRPI0408442A (pt) * | 2003-03-17 | 2006-04-04 | Japan Tobacco Inc | método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato |
JP5546715B2 (ja) * | 2003-03-17 | 2014-07-09 | 日本たばこ産業株式会社 | Cetp阻害剤の医薬組成物 |
NZ542342A (en) * | 2003-04-25 | 2009-05-31 | Gilead Sciences Inc | Antiviral phosphonate analogs |
EP1620109A2 (en) * | 2003-04-25 | 2006-02-01 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
US7407965B2 (en) * | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US7470724B2 (en) * | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
US20090247488A1 (en) * | 2003-04-25 | 2009-10-01 | Carina Cannizzaro | Anti-inflammatory phosphonate compounds |
US7452901B2 (en) * | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
EP1618893A4 (en) * | 2003-04-28 | 2009-08-12 | Sankyo Co | MEANS FOR INCREASING SUGAR CAPACITY |
AU2004233693B2 (en) * | 2003-04-28 | 2007-07-19 | Funahashi, Toru | Adiponectin production enhancer |
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
US7166638B2 (en) * | 2003-05-27 | 2007-01-23 | Nicox S.A. | Statin derivatives |
GB0312896D0 (en) * | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
US7459474B2 (en) * | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US7368468B2 (en) * | 2003-06-18 | 2008-05-06 | Teva Pharmaceutical Industries Ltd. | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them |
PL1638937T3 (pl) * | 2003-06-18 | 2009-06-30 | Teva Pharmaceutical Industries Ltd | Krystaliczna postać XIV soli sodowej fluwastatyny, sposoby jej wytwarzania, kompozycje farmaceutyczne zawierające tę postać oraz sposoby ich stosowania |
CN1838942A (zh) * | 2003-07-11 | 2006-09-27 | 普罗医药公司 | 递送疏水性药物的组合物和方法 |
US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
WO2005021511A1 (en) * | 2003-08-27 | 2005-03-10 | Hetero Drugs Limited | A novel process for amorphous rosuvastatin calcium |
CA2657076A1 (en) * | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin calcium |
US20050053664A1 (en) * | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
GB0321827D0 (en) * | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US20050171207A1 (en) * | 2003-09-26 | 2005-08-04 | Myriad Genetics, Incorporated | Method and composition for combination treatment of neurodegenerative disorders |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
US20070191318A1 (en) * | 2003-10-22 | 2007-08-16 | Yatendra Kumar | Process for the preparation of amorphous rosuvastatin calcium |
WO2005044308A1 (en) * | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
CA2543596A1 (en) * | 2003-11-07 | 2005-05-26 | Jj Pharma, Inc. | Hdl-boosting combination therapy complexes |
US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
EP1997533B8 (en) * | 2003-11-12 | 2014-10-29 | Sino-Med International Alliance, Inc. | Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors |
CA2546601A1 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
CA2546701C (en) * | 2003-11-24 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
ATE507209T1 (de) * | 2003-12-02 | 2011-05-15 | Teva Pharma | Referenzstandard zur charakterisierung von rosuvastatin |
WO2005054207A1 (en) * | 2003-12-04 | 2005-06-16 | Glenmark Pharmaceuticals Limited | Process for the preparation of pyrimidine derivatives |
AU2004308332B2 (en) | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
US20070179166A1 (en) * | 2003-12-24 | 2007-08-02 | Valerie Niddam-Hildesheim | Process for preparation of statins with high syn to anti ratio |
US20050159615A1 (en) * | 2003-12-24 | 2005-07-21 | Entire Interest. | Process for preparation of statins with high syn to anti ratio |
US7851624B2 (en) * | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
US20070161700A1 (en) * | 2004-12-28 | 2007-07-12 | Kowa Company, Ltd. | Inhibitor for the formation of y-secretase complex |
JPWO2005063294A1 (ja) | 2003-12-30 | 2007-12-13 | 興和株式会社 | γ−セクレターゼ複合体形成阻害剤 |
CZ200486A3 (cs) * | 2004-01-16 | 2005-08-17 | Zentiva, A.S. | Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny |
EP1737828A1 (en) * | 2004-01-19 | 2007-01-03 | Ranbaxy Laboratories Limited | Amorphous magnesium salts of rosuvastatin |
US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
EP1563837A1 (en) * | 2004-02-03 | 2005-08-17 | Ferrer Internacional, S.A. | Hypocholesterolemic compositions comprising a statin and an antiflatulent agent |
WO2005079314A2 (en) * | 2004-02-13 | 2005-09-01 | Pro-Pharmaceuticals, Inc. | Compositions and methods used to treat acne and candida |
JP4711952B2 (ja) * | 2004-02-25 | 2011-06-29 | 興和株式会社 | Racタンパク質の核内移行促進剤及びそのスクリーニング方法 |
WO2005079847A1 (ja) | 2004-02-25 | 2005-09-01 | Kowa Company, Ltd. | Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法 |
US7241800B2 (en) | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
GB0406757D0 (en) | 2004-03-26 | 2004-04-28 | Avecia Ltd | Process and compounds |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
CN1323665C (zh) * | 2004-06-16 | 2007-07-04 | 鲁南制药集团股份有限公司 | 治疗高血脂症的组合物 |
US7161004B2 (en) * | 2004-06-21 | 2007-01-09 | Dr. Reddy's Laboratories Limited | Processes to produce intermediates for rosuvastatin |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
US7145040B2 (en) * | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
EP1778220A1 (en) * | 2004-07-12 | 2007-05-02 | Phenomix Corporation | Constrained cyano compounds |
JP2007508379A (ja) * | 2004-07-13 | 2007-04-05 | テバ ファーマシューティカル インダストリーズ リミティド | Tempo媒介型酸化段階を包含するロスバスタチンの調製方法 |
US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
CZ298330B6 (cs) * | 2004-07-19 | 2007-08-29 | Zentiva, A. S. | Zpusob výroby 4-(4-fluorfenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)-5-pyrimidinkarbaldehydu a jeho použití |
AU2005330489B2 (en) | 2004-07-27 | 2011-08-25 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates as anti HIV agents |
EP1773128A2 (en) * | 2004-08-02 | 2007-04-18 | Pro-Pharmaceuticals, Inc. | Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins |
CN100412065C (zh) * | 2004-08-13 | 2008-08-20 | 天津天士力集团有限公司 | 一种4-(对氟苯基)-6-异丙基-2-甲胺基嘧啶-5-甲酸甲酯的合成方法 |
US20070244107A1 (en) * | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
EP1797046A2 (en) * | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
CN1763015B (zh) * | 2004-10-22 | 2011-06-22 | 四川抗菌素工业研究所有限公司 | 一种罗舒伐他汀及其药用盐的制备方法及中间体 |
EP1806332A4 (en) | 2004-10-27 | 2010-03-31 | Daiichi Sankyo Co Ltd | BENZENE COMPOUND HAVING TWO OR MORE TWO SUBSTITUENTS |
JP2008524159A (ja) * | 2004-12-15 | 2008-07-10 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | NEP阻害剤、内因性エンドセリン産生系の阻害剤およびHMGCoAレダクターゼ阻害剤を含有する医薬組成物 |
ATE479662T1 (de) * | 2004-12-23 | 2010-09-15 | Hui Yao | Pyrimidinonverbindungen, ihre herstellung und ihre verwendung |
GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
US7589088B2 (en) * | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7635699B2 (en) * | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
WO2006076598A2 (en) * | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
WO2006076568A2 (en) | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Thiazolopyridines as cannabinoid receptor modulators |
US7368458B2 (en) * | 2005-01-12 | 2008-05-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
WO2006078697A1 (en) * | 2005-01-18 | 2006-07-27 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
CN100351240C (zh) * | 2005-01-19 | 2007-11-28 | 安徽省庆云医药化工有限公司 | 瑞舒伐他汀钙的合成方法 |
CA2594692A1 (en) * | 2005-01-31 | 2006-08-03 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of rosuvastatin calcium salt |
EP1849765A4 (en) * | 2005-02-02 | 2010-05-05 | Ajinomoto Kk | PROCESS FOR PREPARING A PYRIMIDINE COMPOUND |
ES2319461T3 (es) * | 2005-02-10 | 2009-05-07 | Bristol-Myers Squibb Company | Dihidroquinazolinonas como moduladores de 5ht. |
US20070167625A1 (en) * | 2005-02-22 | 2007-07-19 | Anna Balanov | Preparation of rosuvastatin |
US20070037979A1 (en) * | 2005-02-22 | 2007-02-15 | Valerie Niddam-Hildesheim | Preparation of rosuvastatin |
TWI353981B (en) * | 2005-02-22 | 2011-12-11 | Teva Pharma | Preparation of rosuvastatin |
US20070293535A1 (en) * | 2005-02-24 | 2007-12-20 | Kowa Company, Ltd. | Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame |
EP1863773A1 (en) * | 2005-03-22 | 2007-12-12 | Unichem Laboratories Limited | Process for preparation of rosuvastatin |
EP1869005A1 (en) * | 2005-04-04 | 2007-12-26 | Unichem Laboratories Limited | Process for preparation of calcium salt of rosuvastatin |
EP1879881A2 (en) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
CN1307187C (zh) * | 2005-05-16 | 2007-03-28 | 浙江海正药业股份有限公司 | 瑞舒伐他汀及其中间体的制备方法 |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
WO2006125304A1 (en) * | 2005-05-25 | 2006-11-30 | Liponex, Inc. | Pharmaceutical compositions for treating or preventing coronary artery disease |
AR053495A1 (es) * | 2005-05-26 | 2007-05-09 | Bristol Myers Squibb Co | Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas |
WO2006128954A1 (en) * | 2005-06-01 | 2006-12-07 | Fermion Oy | Process for the preparation of n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide |
US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
US20060287342A1 (en) * | 2005-06-17 | 2006-12-21 | Mikkilineni Amarendra B | Triazolopyrimidine heterocycles as cannabinoid receptor modulators |
US7317012B2 (en) * | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
US7572808B2 (en) * | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
US7629342B2 (en) * | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
JP5146965B2 (ja) * | 2005-06-24 | 2013-02-20 | レツク・フアーマシユーテイカルズ・デー・デー | 不純物を含まない非晶質ロスバスタチンカルシウムの調製方法 |
SI1915349T1 (sl) | 2005-06-24 | 2016-05-31 | Lek Pharmaceuticals D.D. | Postopek za pripravo čistega amorfnega rosuvastatin kalcija |
CZ299215B6 (cs) * | 2005-06-29 | 2008-05-21 | Zentiva, A. S. | Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny |
GB0514078D0 (en) * | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
WO2007016353A2 (en) * | 2005-07-28 | 2007-02-08 | Bristol-Myers Squibb Company | Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists |
US7868169B2 (en) * | 2005-08-16 | 2011-01-11 | Teva Pharmaceutical Industries, Ltd. | Crystalline rosuvastatin intermediate |
US20070099994A1 (en) * | 2005-08-16 | 2007-05-03 | Valerie Niddam-Hildesheim | Rosuvastatin calcium with a low salt content |
CN100352821C (zh) * | 2005-08-22 | 2007-12-05 | 鲁南制药集团股份有限公司 | 一种瑞舒伐他汀钙中间体的制备方法 |
CN100436428C (zh) * | 2005-08-22 | 2008-11-26 | 鲁南制药集团股份有限公司 | 瑞舒伐他汀及其盐的制备方法 |
US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
WO2007030302A2 (en) * | 2005-09-01 | 2007-03-15 | Prescient Medical, Inc. | Drugs coated on a device to treat vulnerable plaque |
WO2007035395A2 (en) * | 2005-09-16 | 2007-03-29 | Virginia Commonwealth University Intellectual Property Foundation | Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors |
KR20090113920A (ko) * | 2005-10-03 | 2009-11-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 로수바스타틴의 부분입체 이성질체 정제 |
CA2625290A1 (en) * | 2005-10-04 | 2007-04-12 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
AR056155A1 (es) | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
EP1943215A2 (en) | 2005-10-31 | 2008-07-16 | Brystol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
CN1958593B (zh) * | 2005-11-03 | 2010-05-05 | 上海医药工业研究院 | 一种用于合成瑞舒伐他汀钙的中间体的制备方法 |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
CA2630704C (en) * | 2005-12-20 | 2014-08-19 | Lek Pharmaceuticals D.D. | Pharmaceutical composition |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
WO2007082264A2 (en) * | 2006-01-11 | 2007-07-19 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
AU2007208965B2 (en) * | 2006-01-30 | 2011-12-08 | Cadila Healthcare Limited | A process for manufacturing Rosuvastatin Potassium and crystalline and amorphous forms thereof |
US7553836B2 (en) * | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
KR101588539B1 (ko) | 2006-03-07 | 2016-01-25 | 바스프 엔자임스 엘엘씨 | 알돌라제, 이것을 코딩하는 핵산과 그 제조 방법 및 사용 방법 |
US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
AU2007243282A1 (en) * | 2006-04-28 | 2007-11-08 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of cardiovascular disease |
WO2007125547A2 (en) * | 2006-05-03 | 2007-11-08 | Manne Satyanarayana Reddy | Novel process for statins and its pharmaceutically acceptable salts thereof |
US20100022457A1 (en) * | 2006-05-26 | 2010-01-28 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
EP2033646A4 (en) | 2006-06-29 | 2009-11-18 | Kowa Co | PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
US20080044326A1 (en) * | 2006-07-04 | 2008-02-21 | Esencia Co., Ltd. | Sterilizer for baby products |
PL2359826T3 (pl) | 2006-07-05 | 2014-04-30 | Astrazeneca Ab | Połączenie inhibitora reduktazy HMG-CoA rosuwastatyny z inhibitorem fosfodiesterazy 4, takim jak roflumilast, N-tlenek roflumilastu, do leczenia chorób zapalnych płuc |
US7795291B2 (en) | 2006-07-07 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method |
WO2008015563A2 (en) * | 2006-08-04 | 2008-02-07 | Glenmark Pharmaceuticals Limited | Salts of rosuvastatin and processes for their preparation |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
HU227610B1 (en) * | 2006-09-18 | 2011-09-28 | Richter Gedeon Nyrt | Pharmaceutical compositions containing rosuvastatin potassium |
HUE028475T2 (en) | 2006-10-09 | 2016-12-28 | Msn Laboratories Private Ltd | A novel process for the preparation of statins and their pharmaceutically acceptable salts |
WO2008053334A2 (en) * | 2006-10-31 | 2008-05-08 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin calcium |
EP2089355A2 (en) | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
US20100069635A1 (en) * | 2006-11-29 | 2010-03-18 | Dr. Reddy's Laboratories Ltd. | Rosuvastatin dehydroabietylamine salt |
US8212034B2 (en) * | 2006-12-13 | 2012-07-03 | Aurobindo Pharma Ltd. | Process for preparing rosuvastatin calcium |
WO2008093205A2 (en) * | 2007-01-31 | 2008-08-07 | Orchid Chemicals & Pharmaceuticals Limited | A method for the purification of rosuvastatin intermediate |
EP2125754B1 (en) * | 2007-02-08 | 2012-04-11 | Aurobindo Pharma Limited | Process for preparation of rosuvastatin calcium |
PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
WO2008124121A1 (en) * | 2007-04-06 | 2008-10-16 | Scidose, Llc | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
US20080249156A1 (en) * | 2007-04-09 | 2008-10-09 | Palepu Nageswara R | Combinations of statins and anti-obesity agent and glitazones |
MX2009010925A (es) * | 2007-04-09 | 2009-11-02 | Scidose Llc | Combinaciones de estatinas y agente anti-obesidad. |
US8546394B2 (en) | 2007-04-17 | 2013-10-01 | Bristol-Myers Squibb Company | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors |
ES2415206T3 (es) | 2007-04-18 | 2013-07-24 | Teva Pharmaceutical Industries, Ltd. | Un proceso para preparar productos intermedios de inhibidores de la HMG-CoA reductasa |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
JP4896220B2 (ja) | 2007-04-27 | 2012-03-14 | 国立大学法人九州大学 | 肺疾患治療薬 |
CN101754972A (zh) * | 2007-05-18 | 2010-06-23 | 百时美施贵宝公司 | Sglt2抑制剂的晶体结构及其制备方法 |
AU2008287542C1 (en) | 2007-06-01 | 2015-01-22 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
EP2546232A1 (en) | 2007-06-20 | 2013-01-16 | Merck Sharp & Dohme Corp. | Diphenyl Substituted Alkanes |
US20090011994A1 (en) * | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
EP2178890A1 (en) * | 2007-07-12 | 2010-04-28 | Teva Pharmaceutical Industries Ltd. | Purification of rosuvastatin intermediate by thin film evaporation and chemical method |
JP2010534722A (ja) * | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
EP2022784A1 (en) * | 2007-08-08 | 2009-02-11 | LEK Pharmaceuticals D.D. | Process for the preparation of methyl ester of rosuvastatin |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
WO2009027081A2 (en) * | 2007-08-28 | 2009-03-05 | Ratiopharm Gmbh | Process for preparing pentanoic diacid derivatives |
CN101376647B (zh) * | 2007-08-31 | 2010-12-08 | 中山奕安泰医药科技有限公司 | 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法 |
US20090082380A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched rosuvastatin |
HU230981B1 (hu) * | 2007-10-12 | 2019-08-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin só előállítására |
HU230637B1 (hu) * | 2007-10-12 | 2017-05-29 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin intermedierek előállítására |
JP2011503081A (ja) | 2007-11-01 | 2011-01-27 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、AP−1および/またはNF−κB活性の調節剤として有用な非ステロイド性化合物、並びにその使用 |
RS58486B1 (sr) | 2008-01-11 | 2019-04-30 | Reata Pharmaceuticals Inc | Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti |
TR200800269A2 (tr) * | 2008-01-15 | 2009-08-21 | Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. | Stabil farmasötik formülasyon ve hazırlama yöntemleri |
WO2009143776A1 (zh) | 2008-05-27 | 2009-12-03 | 常州制药厂有限公司 | 瑞舒伐他汀钙盐的制备方法及其中间体 |
CN101591301B (zh) * | 2008-05-27 | 2011-01-12 | 常州制药厂有限公司 | 一种3,5-二羟基庚-6-烯酸衍生物的制备方法 |
CN101591302B (zh) * | 2008-05-27 | 2011-08-31 | 常州制药厂有限公司 | 一种庚烯酸酯衍生物的制备方法 |
PE20091928A1 (es) * | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
EP2309992B1 (en) | 2008-06-27 | 2017-10-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising a statin |
EP2138165A1 (en) | 2008-06-27 | 2009-12-30 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising a statin |
WO2010005986A1 (en) | 2008-07-08 | 2010-01-14 | Gilead Sciences, Inc. | Salts of hiv inhibitor compounds |
EP2161024A1 (de) | 2008-09-05 | 2010-03-10 | Universitätsklinikum Hamburg-Eppendorf | Kombinationspräparat zur Behandlung von Krebs |
WO2010038124A1 (en) * | 2008-09-30 | 2010-04-08 | Aurobindo Pharma Limited | An improved process for preparing pyrimidine propenaldehyde |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
EP2373609B1 (en) | 2008-12-19 | 2013-10-16 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
EP2327682A1 (en) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
WO2010081861A1 (en) | 2009-01-14 | 2010-07-22 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of rosuvastatin |
CN102317267A (zh) | 2009-01-15 | 2012-01-11 | 埃吉斯药物股份公开有限公司 | 制备罗苏伐他汀盐的方法 |
US8487105B2 (en) | 2009-01-19 | 2013-07-16 | Msn Laboratories Limited | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof |
EP2264015A1 (en) | 2009-02-02 | 2010-12-22 | LEK Pharmaceuticals d.d. | Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof |
WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
KR101160152B1 (ko) * | 2009-02-24 | 2012-06-27 | 한미사이언스 주식회사 | 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물 |
GB0904100D0 (en) | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Use of rosuvastatin lactols as medicaments |
GB0904104D0 (en) | 2009-03-10 | 2009-04-22 | Bradford Pharma Ltd | Atorvastatin and rosuvastatin derivatives |
TR200902077A2 (tr) | 2009-03-17 | 2010-01-21 | Sanovel İlaç San.Veti̇c.A.Ş. | Stabil rosuvastatin kompozisyonları |
MX2011009852A (es) | 2009-03-27 | 2011-09-29 | Bristol Myers Squibb Co | Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv. |
TW201039815A (en) | 2009-04-13 | 2010-11-16 | Resolvyx Pharmaceuticals Inc | Compositions and methods for the treatment of inflammation |
US8470805B2 (en) | 2009-04-30 | 2013-06-25 | Kaohsiung Medical University | Processes for preparing piperazinium salts of KMUP and use thereof |
HUP0900285A2 (en) | 2009-05-07 | 2011-01-28 | Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag | Rosuvastatin salts and preparation thereof |
TR200904341A2 (tr) | 2009-06-03 | 2010-12-21 | Bi̇lgi̇ç Mahmut | Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler. |
KR101157314B1 (ko) | 2009-06-05 | 2012-06-15 | 주식회사종근당 | 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법 |
EP2448919A2 (en) | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
WO2011018185A2 (en) | 2009-08-13 | 2011-02-17 | Synthon B.V. | Pharmaceutical tablet comprising rosuvastatin calcium |
US8846915B2 (en) | 2009-08-17 | 2014-09-30 | Aurobindo Pharma Ltd. | Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester |
PL2498758T3 (pl) | 2009-11-13 | 2019-02-28 | Astrazeneca Ab | Formulacje tabletek dwuwarstwowych |
MX2012005365A (es) | 2009-11-13 | 2012-05-29 | Bristol Myers Squibb Co | Formulaciones de tableta de liberacion inmediata. |
CA2780938A1 (en) | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
JP2011121949A (ja) | 2009-12-14 | 2011-06-23 | Kyoto Univ | 筋萎縮性側索硬化症の予防および治療用医薬組成物 |
EP2336116A1 (en) | 2009-12-16 | 2011-06-22 | LEK Pharmaceuticals d.d. | Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof |
WO2011074016A1 (en) | 2009-12-17 | 2011-06-23 | Matrix Laboratories Ltd | Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same |
US8987444B2 (en) | 2010-01-18 | 2015-03-24 | Msn Laboratories Private Limited | Process for the preparation of amide intermediates and their use thereof |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
CN102212082B (zh) * | 2010-04-05 | 2015-03-04 | 重庆博腾制药科技股份有限公司 | 瑞舒伐他汀钙中间体及制备方法 |
WO2011130459A1 (en) | 2010-04-14 | 2011-10-20 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
CN102219749B (zh) * | 2010-04-14 | 2013-07-17 | 上海京新生物医药有限公司 | 一种制备瑞苏伐他汀钙的方法 |
US8372877B2 (en) | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
EP2560970A1 (en) | 2010-04-23 | 2013-02-27 | Ranbaxy Laboratories Limited | NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS |
EP2566465A2 (en) | 2010-05-04 | 2013-03-13 | Mahmut Bilgic | Stable rosuvastatin formulations |
WO2011141934A1 (en) | 2010-05-13 | 2011-11-17 | Matrix Laboratories Ltd. | An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors |
EP2575757A1 (en) | 2010-06-03 | 2013-04-10 | Mahmut Bilgic | Water soluble formulation comprising a combination of amlodipine and a statin |
TR201005326A2 (tr) | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Çoklu dozaj formları. |
EP2588474A4 (en) | 2010-07-01 | 2014-07-23 | Yuhan Corp | PROCESS FOR PREPARING HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF |
EP2423195A1 (en) | 2010-07-26 | 2012-02-29 | LEK Pharmaceuticals d.d. | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof |
CN101955463B (zh) * | 2010-08-04 | 2012-01-04 | 重庆博腾制药科技股份有限公司 | 瑞舒伐他汀钙中间体的制备方法 |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
MX2010011006A (es) * | 2010-10-06 | 2012-04-18 | Senosiain S A De C V Lab | Nueva sal de un derivado de pirimidina. |
CN103153299A (zh) | 2010-10-06 | 2013-06-12 | 国立大学法人东京大学 | 淋巴水肿预防治疗剂 |
TWI462739B (zh) | 2010-11-02 | 2014-12-01 | Univ Kaohsiung Medical | Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途 |
TR201009399A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Hızlı çözünen efervesan rosuvastatin formülasyonları. |
WO2012063115A2 (en) | 2010-11-11 | 2012-05-18 | Jubilant Life Sciences Ltd. | Process for the preparation of rosuvastatin calcium via novel amine intermediate |
HU230737B1 (hu) | 2010-11-16 | 2018-01-29 | EGIS Gyógyszergyár Nyrt | Eljárás rosuvastatin só előállítására |
WO2012073256A1 (en) | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
HU229260B1 (en) | 2010-11-29 | 2013-10-28 | Egis Gyogyszergyar Nyrt | Process for preparation of rosuvastatin salts |
HU230987B1 (hu) | 2010-11-29 | 2019-08-28 | Egis Gyógyszergyár Nyrt. | Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására |
TWI631963B (zh) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法 |
CN102584717B (zh) * | 2011-01-17 | 2014-12-10 | 浙江九洲药业股份有限公司 | 用于制备罗苏伐他汀的中间体及相关制备方法和用途 |
SI2665723T1 (sl) | 2011-01-18 | 2015-11-30 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Postopek priprave statinov v prisotnosti baze |
US8933113B2 (en) | 2011-01-20 | 2015-01-13 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
WO2012101253A1 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
WO2012139495A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
WO2012143308A1 (en) * | 2011-04-18 | 2012-10-26 | Basf Se | Multicomponent crystalline system of rosuvastatin calcium salt and vanillin |
CA2835364C (en) | 2011-05-20 | 2018-10-02 | Astrazeneca Uk Limited | Pharmaceutical composition of rosuvastatin calcium |
WO2012172564A1 (en) * | 2011-05-25 | 2012-12-20 | Dr. Reddy's Laboratories Limited | Process for preparation of rosuvastatin calcium |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
WO2013046222A2 (en) * | 2011-08-10 | 2013-04-04 | Glenmark Generics Limited | A process for the preparation of amorphous rosuvastatin calcium |
EP3536712B1 (en) | 2011-09-16 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) |
US9505730B2 (en) | 2011-10-13 | 2016-11-29 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
AU2012345473B2 (en) | 2011-11-28 | 2017-05-25 | Mylan Laboratories Ltd | Process for producing chiral statin side chain intermediates employing candida|antarctica lipase B |
EP2602249B1 (en) | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
US20150010630A1 (en) | 2011-12-29 | 2015-01-08 | Trustees Of Tufts College | Functionalization of biomaterials to control regeneration and inflammation responses |
WO2013113067A1 (en) | 2012-02-02 | 2013-08-08 | The University Of Sydney | Improvements in tear film stability |
DK2844233T3 (da) | 2012-05-01 | 2020-07-13 | Althera Life Sciences Llc | Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme |
CN104364266A (zh) | 2012-06-15 | 2015-02-18 | 霍夫曼-拉罗奇有限公司 | 抗-pcsk9抗体,制剂,剂量给药,和使用方法 |
US8729092B2 (en) * | 2012-09-24 | 2014-05-20 | Terence J. Scallen | Rosuvastatin enantiomer compounds |
CN103709107B (zh) * | 2012-09-29 | 2016-04-20 | 安徽省庆云医药化工有限公司 | 瑞舒伐他汀甲酯的新晶型及其制备方法 |
CN103044339A (zh) * | 2012-10-15 | 2013-04-17 | 武汉市江润精细化工有限责任公司 | 瑞舒伐他汀钙中间体的制备方法 |
DK2925735T3 (da) | 2012-11-20 | 2019-06-17 | Lexicon Pharmaceuticals Inc | Inhibitorer for natriumglucose-cotransporter 1 |
WO2014108795A2 (en) | 2013-01-10 | 2014-07-17 | Aurobindo Pharma Limited | An improved process for the preparation of chiral diol sulfones and statins |
ITVI20130039A1 (it) | 2013-02-20 | 2014-08-21 | F I S Fabbrica Italiana Sint I S P A | Processo per la preparazione di intermedi chiave per la sintesi di statine |
CN105163734A (zh) | 2013-03-12 | 2015-12-16 | 株式会社Lg生命科学 | 包含缬沙坦及罗舒伐他汀钙的复合制剂及其制造方法 |
MX368148B (es) | 2013-03-14 | 2019-09-20 | Boryung Pharm | Farmaco de combinacion farmaceutica. |
EP2986599A1 (en) | 2013-04-17 | 2016-02-24 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
WO2014197752A1 (en) | 2013-06-07 | 2014-12-11 | Regeneron Pharmaceuticals, Inc. | Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9 |
WO2014203045A1 (en) | 2013-06-20 | 2014-12-24 | Lupin Limited | A novel, green and cost effective process for synthesis of tert-butyl (3r,5s)-6-oxo-3,5-dihydroxy-3,5-o-isopropylidene-hexanoate |
TW201636015A (zh) | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
EP3022213B1 (en) | 2013-07-16 | 2017-06-21 | Suven Life Sciences Limited | Process for the preparation of rosuvastatin calcium and preparation of its novel intermediates |
WO2015027021A1 (en) | 2013-08-22 | 2015-02-26 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
KR20160081978A (ko) | 2013-11-12 | 2016-07-08 | 사노피 바이오테크놀로지 | Pcsk9 억제제의 사용을 위한 투약 요법 |
JP6536871B2 (ja) | 2013-12-02 | 2019-07-03 | 国立大学法人京都大学 | Fgfr3病の予防および治療剤ならびにそのスクリーニング方法 |
CN103724278B (zh) * | 2013-12-12 | 2019-03-29 | 江苏阿尔法药业有限公司 | 他汀类中间体及其衍生物的制备方法 |
KR20150079373A (ko) | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
EP3103878A4 (en) | 2014-02-06 | 2017-08-16 | API Corporation | Rosuvastatin calcium and process for producing intermediate thereof |
US10449210B2 (en) | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
WO2015131405A1 (zh) * | 2014-03-07 | 2015-09-11 | 凯莱英医药集团(天津)股份有限公司 | 用于制备瑞舒伐他汀钙的中间体化合物以及由其制备瑞舒伐他汀钙的方法 |
CN103896979B (zh) * | 2014-03-31 | 2015-03-18 | 南京欧信医药技术有限公司 | 一种化合物的合成方法 |
CN103951552B (zh) * | 2014-04-11 | 2015-09-30 | 浙江宏元药业有限公司 | 瑞舒伐他汀中间体及其制备方法 |
CN104151252B (zh) * | 2014-05-07 | 2016-09-28 | 兰州大学 | 一种制备[6-异丙基-4-(4-氟苯基)-2-硫基-5-基]甲酸酯的方法 |
CN106572997A (zh) | 2014-05-30 | 2017-04-19 | 辉瑞公司 | 作为选择性雄激素受体调节剂的腈衍生物 |
PL3169353T3 (pl) | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
WO2016056658A1 (ja) * | 2014-10-10 | 2016-04-14 | 株式会社エーピーアイ コーポレーション | スタチン系化合物の精製方法 |
CN104356155B (zh) * | 2014-10-20 | 2017-01-18 | 浙江新东港药业股份有限公司 | 一种(s)‑叔丁基二甲基硅氧基‑戊二酸单酰胺的制备方法 |
CN104529909B (zh) * | 2014-12-26 | 2016-08-24 | 江西富祥药业股份有限公司 | 一种瑞舒伐他汀钙中间体的结晶方法 |
CN104592130A (zh) * | 2014-12-30 | 2015-05-06 | 江苏阿尔法药业有限公司 | 一种瑞舒伐他汀主链的新的制备方法 |
CN104628653B (zh) * | 2015-01-28 | 2018-04-03 | 湖北益泰药业有限公司 | 合成瑞舒伐他汀钙关键中间体的方法 |
KR20160126700A (ko) | 2015-04-24 | 2016-11-02 | 미래파인켐 주식회사 | 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법 |
CN104829600B (zh) * | 2015-05-05 | 2017-11-07 | 浙江新东港药业股份有限公司 | 一种合成瑞舒伐他汀的中间体的合成工艺 |
CA2995645A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
CN108472249A (zh) | 2015-10-23 | 2018-08-31 | 林德拉有限公司 | 用于治疗剂缓释的胃驻留系统及其使用方法 |
CN105367502A (zh) * | 2015-12-07 | 2016-03-02 | 浙江宏元药业有限公司 | 瑞舒伐他汀钙中间体及制备瑞舒伐他汀钙中间体和瑞舒伐他汀钙的方法 |
US10626093B2 (en) | 2016-04-18 | 2020-04-21 | Morepen Loboratories Limited | Polymorphic form of crystalline rosuvastatin calcium and novel processes for crystalline as well as amorphous rosuvastatin calcium |
AU2017336154B2 (en) | 2016-09-30 | 2023-11-09 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained delivery of adamantane-class drugs |
BR112019015107A2 (pt) | 2017-01-23 | 2020-03-10 | Dong Wha Pharm. Co., Ltd. | Formulação de complexo compreendendo inibidor de hmg-coa redutase e clopidogrel |
CN107698518A (zh) * | 2017-06-20 | 2018-02-16 | 迪沙药业集团(天津)药物研究有限公司 | 一种瑞舒伐他汀钙差向异构体杂质的制备方法 |
SI3661937T1 (sl) | 2017-08-01 | 2021-11-30 | Gilead Sciences, Inc. | Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
EP3737676B1 (en) * | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
WO2019216313A1 (ja) | 2018-05-08 | 2019-11-14 | 国立大学法人岡山大学 | 心血管疾患に有用な医薬 |
WO2020017575A1 (ja) | 2018-07-19 | 2020-01-23 | 国立大学法人京都大学 | 多能性幹細胞由来の板状軟骨およびその製造方法 |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP3833668A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
CA3113037A1 (en) | 2018-09-26 | 2020-04-02 | Lexicon Pharmaceuticals, Inc. | Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis |
JP7224001B2 (ja) | 2018-12-21 | 2023-02-17 | 国立大学法人京都大学 | ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物 |
US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
CN109796414B (zh) * | 2019-02-26 | 2022-05-20 | 中国药科大学 | 一种采用微通道模块化反应装置连续制备瑞舒伐他汀中间体的方法 |
MX2021010987A (es) | 2019-03-13 | 2021-12-15 | National Univ Corporation Hamamatsu Univ School Of Medicine | Composicion farmaceutica para el tratamiento contra aneurisma aortico. |
BR112022001514A2 (pt) | 2019-07-31 | 2022-03-22 | Intas Pharmaceuticals Ltd | Composição farmacêutica multicamada e processo para a preparação de uma composição farmacêutica |
WO2021019499A1 (en) | 2019-07-31 | 2021-02-04 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Solid oral multiple-unit immediate release compositions, methods and uses thereof |
JPWO2021100848A1 (zh) | 2019-11-22 | 2021-05-27 | ||
AU2020408148A1 (en) | 2019-12-17 | 2022-06-16 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
EP4108260A4 (en) | 2020-02-21 | 2024-03-06 | Jsr Corp | COMPOSITION FOR RELIEF PULMONARY HYPERTENSION, METHOD FOR PREDICTING THE PROGNOSIS OF PULMONARY HYPERTENSION, METHOD FOR AIDING IN DETERMINING THE SEVERITY OF PULMONARY HYPERTENSION, AND METHOD FOR AIDING IN THE DIAGNOSIS OF PULMONARY HYPERTENSION |
WO2022228551A1 (zh) * | 2021-04-30 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
GB2622822A (en) | 2022-09-28 | 2024-04-03 | Novumgen Ltd | A rapidly disintegrating tablet of rosuvastatin and its process of preparation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE132496T1 (de) | 1987-07-10 | 1996-01-15 | Hoechst Ag | 3-desmethyl-mevalonsäurederivate, verfahren zu ihrer herstellung, pharmazeutische präparate auf basis dieser verbindungen, ihre verwendung sowie zwischenprodukte |
EP0308736A3 (en) | 1987-09-12 | 1990-02-14 | Nissan Chemical Industries Ltd. | Pyrimidine type mevalonolactones |
US4868185A (en) | 1987-12-10 | 1989-09-19 | Warner-Lambert Company | 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
NO890521L (no) | 1988-02-25 | 1989-08-28 | Bayer Ag | Substituerte pyrimidiner. |
KR900701778A (ko) * | 1988-10-06 | 1990-12-04 | 예안 크라머, 한스 루돌프 하우스 | 피리미디닐- 치환된 하이드록시산, 락톤 및 에스테르, 및 이를 함유하는 약학적 조성물 |
-
1992
- 1992-05-28 JP JP4164009A patent/JP2648897B2/ja not_active Expired - Lifetime
- 1992-06-12 US US07/897,793 patent/US5260440A/en not_active Ceased
- 1992-06-29 TW TW081105115A patent/TW203044B/zh not_active IP Right Cessation
- 1992-06-30 HU HU9202179A patent/HU219407B/hu unknown
- 1992-06-30 DE DE69231530T patent/DE69231530T2/de not_active Expired - Lifetime
- 1992-06-30 ES ES92111090T patent/ES2153824T3/es not_active Expired - Lifetime
- 1992-06-30 HU HU0004863A patent/HU220624B1/hu unknown
- 1992-06-30 EP EP92111090A patent/EP0521471B1/en not_active Expired - Lifetime
- 1992-06-30 PT PT92111090T patent/PT521471E/pt unknown
- 1992-06-30 DE DE122009000017C patent/DE122009000017I2/de active Active
- 1992-06-30 DK DK92111090T patent/DK0521471T3/da active
- 1992-06-30 AT AT92111090T patent/ATE197149T1/de active
- 1992-07-01 KR KR1019920011690A patent/KR960005951B1/ko not_active IP Right Cessation
- 1992-07-02 CA CA002072945A patent/CA2072945C/en not_active Expired - Lifetime
-
1998
- 1998-08-27 US US09/141,731 patent/USRE37314E1/en not_active Expired - Lifetime
- 1998-12-11 HK HK98113237A patent/HK1011986A1/xx not_active IP Right Cessation
-
2001
- 2001-01-04 GR GR20010400007T patent/GR3035189T3/el unknown
- 2001-06-27 CY CY0100015A patent/CY2226B1/xx unknown
- 2001-10-09 GE GE4516A patent/GEP20022693B/en unknown
-
2003
- 2003-04-25 NL NL300125C patent/NL300125I2/nl unknown
- 2003-09-24 LU LU91042C patent/LU91042I2/fr unknown
-
2010
- 2010-02-10 CL CL2010000113A patent/CL2010000113A1/es unknown
-
2015
- 2015-06-15 CY CY2004008C patent/CY2004008I2/el unknown
Also Published As
Publication number | Publication date |
---|---|
HU220624B1 (hu) | 2002-03-28 |
ATE197149T1 (de) | 2000-11-15 |
JP2648897B2 (ja) | 1997-09-03 |
KR960005951B1 (ko) | 1996-05-06 |
DK0521471T3 (da) | 2001-02-05 |
CY2004008I2 (el) | 2016-10-05 |
KR930002325A (ko) | 1993-02-23 |
GEP20022693B (en) | 2002-05-10 |
HK1011986A1 (en) | 1999-07-23 |
JPH05178841A (ja) | 1993-07-20 |
EP0521471B1 (en) | 2000-10-25 |
DE122009000017I2 (de) | 2010-10-21 |
US5260440A (en) | 1993-11-09 |
CY2004008I1 (el) | 2010-07-28 |
DE122009000017I1 (de) | 2009-11-05 |
CA2072945C (en) | 2001-07-31 |
LU91042I2 (fr) | 2003-11-24 |
HU9202179D0 (en) | 1992-10-28 |
NL300125I1 (nl) | 2003-07-01 |
GR3035189T3 (en) | 2001-04-30 |
ES2153824T3 (es) | 2001-03-16 |
CL2010000113A1 (es) | 2010-07-02 |
DE69231530D1 (de) | 2000-11-30 |
HU0004863D0 (zh) | 2001-02-28 |
NL300125I2 (nl) | 2003-08-01 |
EP0521471A1 (en) | 1993-01-07 |
CY2226B1 (en) | 2003-04-18 |
CA2072945A1 (en) | 1993-01-02 |
USRE37314E1 (en) | 2001-08-07 |
HU219407B (hu) | 2001-04-28 |
PT521471E (pt) | 2001-04-30 |
DE69231530T2 (de) | 2001-06-13 |
HUT61531A (en) | 1993-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW203044B (zh) | ||
EP0114027B1 (en) | Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals | |
EP0235164B1 (en) | Imidazole analogs of mevalonolactone and derivatives thereof | |
KR960009434B1 (ko) | 3-데메틸메발론산 유도체, 이의 제조방법 및 중간체 | |
EP2752407B1 (en) | Crystalline rosuvastatin calcium trihydrate | |
US6673923B2 (en) | Pyrazole antimicrobial agents | |
KR20070043779A (ko) | 4-페닐-피리미딘-2-카르보니트릴 유도체 | |
JP3068665B2 (ja) | ピロ−ル誘導体 | |
WO1990005132A1 (en) | Substituted allylamine derivatives, process for their preparation and their use | |
JP3197971B2 (ja) | 5−カルボアルコキシピリミジン誘導体の合成方法 | |
US5986106A (en) | Process for preparing 4-substituted-1H-indole-3-glyoxamides | |
US5446162A (en) | Process for the production of 7-acylindoles | |
JPH02275878A (ja) | ピラゾロピリジン系メバロノラクトン類 | |
US5382672A (en) | Preparation of derivatives of benzeneborinic acid | |
NL7906554A (nl) | Hydroxyazijnzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten. | |
US6734303B2 (en) | Process for the production of quinazolines | |
JP3887893B2 (ja) | 4−[2−(4−(トリフルオロメトキシ)フェニル)エチルアミノ]ピリミジン誘導体の製法、並びに製造中間体及びその製法 | |
TWI236479B (en) | Process for preparing N-[5-(diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethanesulphonamide | |
JP3799580B2 (ja) | N−置換−n−スルホニルアミド類の製造方法 | |
AU652852B2 (en) | N,N',N'-trisubstituted-5-bis-aminomethylene-13-dioxane-4, 6-dione inhibitors of acyl-CoA:cholesterol-acyl transferase | |
CA2797350A1 (en) | Co-crystal intermediates of rosuvastatin and methods of using same | |
JPS5916879A (ja) | N−置換イミダゾ−ル類の製造法 | |
JPH0629257B2 (ja) | フエニルピリミジン誘導体 | |
PL185092B1 (pl) | Sposób otrzymywania 5-(dihydroksyborylo)-2,4-bis(alkoksy)pirymidyny | |
JPS5995260A (ja) | スルホン酸エステル誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |